Top Page
GlaxoSmithKline
(LSE:GSK)
GlaxoSmithKline (GSK) vs. iShares MSCI United Kingdom ETF (EWC)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 31.53B | 31.38B | 30.33B | 29.32B | 34.11B | 34.10B | Gross Profit |
| 22.58B | 22.33B | 21.76B | 19.77B | 22.51B | 22.39B | EBIT |
| 5.09B | 4.02B | 6.75B | 6.43B | 6.20B | 7.78B | EBITDA |
| 8.24B | 6.67B | 9.14B | 8.63B | 7.76B | 10.16B | Net Income Common Stockholders |
| 3.15B | 2.58B | 4.93B | 4.92B | 4.38B | 5.75B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.09B | 3.89B | 5.69B | 7.88B | 4.33B | 6.37B | Total Assets |
| 58.51B | 59.46B | 59.01B | 60.15B | 79.10B | 80.43B | Total Debt |
| 17.77B | 16.99B | 18.02B | 20.99B | 24.17B | 27.15B | Net Debt |
| 14.98B | 13.12B | 15.08B | 17.26B | 19.90B | 20.86B | Total Liabilities |
| 45.28B | 46.38B | 46.21B | 50.05B | 57.76B | 59.62B | Stockholders Equity |
| 13.84B | 13.67B | 13.35B | 10.60B | 15.05B | 14.59B |
| Cash Flow | Free Cash Flow | ||||
| 3.64B | 3.57B | 4.42B | 5.14B | 5.02B | 6.20B | Operating Cash Flow |
| 6.50B | 6.55B | 6.77B | 7.40B | 7.95B | 8.44B | Investing Cash Flow |
| -2.26B | -1.23B | -1.59B | -8.77B | -1.78B | 2.16B | Financing Cash Flow |
| -2.54B | -4.73B | -5.64B | 823.00M | -7.59B | -10.13B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | £162.57B | 26.59 | 19.90% | 2.34% | 13.74% | 21.45% | |
80 Outperform | £5.81B | 39.09 | 11.12% | 1.78% | 3.94% | 41.63% | |
76 Outperform | £9.38B | 29.04 | 7.78% | 2.70% | 1.85% | 51.77% | |
73 Outperform | £58.44B | 18.75 | 22.52% | 4.21% | 2.57% | -30.13% | |
71 Outperform | £4.66B | 16.64 | 15.79% | 2.93% | 5.83% | 83.35% | |
53 Neutral | $5.19B | 3.33 | -45.04% | 2.83% | 17.58% | -0.66% | |
| $37.65B | 3.74 | 13.12% | 5.94% | ― | ― |
GlaxoSmithKline Corporate Events
GSK has announced the repurchase of 530,805 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which is part of a non-discretionary agreement, increases GSK’s treasury shares to 216,087,927, representing 5.27% of the company’s voting rights. The buyback is a strategic move to optimize capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK and Spero Therapeutics announced the early termination of the Phase III PIVOT-PO trial for tebipenem HBr due to its efficacy in treating complicated urinary tract infections (cUTIs). This investigational oral antibiotic could become the first oral carbapenem for cUTIs in the US, potentially reducing hospitalizations and healthcare costs. The trial’s success highlights GSK’s expanding anti-infectives portfolio and its commitment to combating antimicrobial resistance. The data will be included in a planned FDA filing in the second half of 2025.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 523,548 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a non-discretionary agreement and contributes to GSK’s strategy of managing its capital structure, with the purchased shares held as treasury shares. The buyback program is significant for shareholders as it affects the total voting rights and share distribution, with implications for shareholder notifications under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 537,661 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction increases the company’s treasury shares to 215,033,574, representing 5.2444% of the total shares with voting rights, potentially impacting shareholder calculations under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Blenrep for treating relapsed or refractory multiple myeloma in combination with other therapies. This recommendation follows successful phase III trials showing superior efficacy and safety profiles. If approved, Blenrep combinations could significantly impact treatment options for multiple myeloma, offering a new mechanism of action and addressing unmet needs in both academic and community settings. The decision by the European Commission is expected in Q3 2025, with potential implications for GSK’s market positioning and stakeholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced that the US FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This approval, based on the positive results from the MATINEE and METREX phase III trials, marks a significant advancement in COPD treatment, offering hope for improved care for patients who are inadequately controlled on inhaled triple therapy. The approval is expected to impact over a million patients in the US, potentially reducing hospitalizations and emergency department visits. Mepolizumab is the only biologic approved for this patient group, providing a new treatment option for those with a blood eosinophil count starting at 150 cells/μL.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 547,990 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, and the purchase contributes to the company’s broader financial strategy, impacting its total voting rights and share distribution.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 567,590 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on May 21, 2025, aims to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 213,947,923 ordinary shares in treasury, with 4,101,310,936 shares remaining in issue. The buyback program reflects GSK’s strategic financial management to optimize its capital allocation and potentially improve its stock market performance.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 570,340 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and aims to enhance shareholder value by holding these shares in treasury, thereby potentially impacting the company’s market positioning and stakeholder interests.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by its Non-Executive Director, Dr. Hal Barron, and SVP and Group General Counsel, James Ford. These acquisitions were made through the reinvestment of dividends in their respective GSK savings plans. The transactions were conducted on the New York Stock Exchange, reflecting GSK’s ongoing commitment to aligning executive interests with shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 565,355 of its own ordinary shares as part of its ongoing buyback program. These shares, purchased at an average price of 1,394.81 pence, will be held in treasury, contributing to the company’s strategy to manage its capital structure effectively. This transaction reflects GSK’s commitment to returning value to shareholders and maintaining a balanced capital allocation approach.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 558,662 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at a volume-weighted average price of 1,391.34 pence, will be held as treasury shares. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited and reflects GSK’s strategy to manage its capital structure effectively. Following this transaction, GSK holds 212,244,638 shares in treasury, impacting the total voting rights available to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that its drug Blenrep, in combination with other treatments, has been approved by Japan’s Ministry of Health, Labour and Welfare for use in adults with relapsed or refractory multiple myeloma. This approval is based on positive results from the DREAMM-7 and DREAMM-8 phase III trials, which demonstrated superior efficacy in terms of progression-free survival and overall survival compared to standard treatments. The approval marks the second major regulatory endorsement for Blenrep combinations, following the UK’s authorization, and highlights the drug’s potential to redefine treatment outcomes for multiple myeloma patients. Blenrep’s unique mechanism as an anti-BCMA antibody-drug conjugate offers a differentiated approach, with manageable side effects, making it suitable for a wide range of patients in various treatment settings.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 569,883 of its own ordinary shares as part of its ongoing share buyback program. This move, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and market confidence.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 591,951 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares. This move is part of a non-discretionary agreement initiated in February 2025, and since then, GSK has bought back a total of 42,045,790 shares. The buyback program aims to optimize the company’s capital structure and return value to shareholders, potentially impacting GSK’s market positioning and shareholder interests.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a non-discretionary agreement initiated in February 2025, and the purchased shares will be held as treasury shares. The buyback is a strategic move to optimize the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced its acquisition of efimosfermin alfa from Boston Pharmaceuticals, a promising phase III-ready specialty medicine aimed at treating steatotic liver disease (SLD), a condition affecting up to 5% of the global population. This acquisition, valued at up to $2 billion, significantly enhances GSK’s hepatology pipeline, offering potential new treatment options for SLD and aligning with the company’s R&D focus on immune system-related science. Efimosfermin has shown potential to reverse liver fibrosis and improve patient outcomes, with a first launch expected in 2029, positioning GSK to address a significant unmet medical need and potentially save the US healthcare system substantial costs over the next two decades.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of ordinary shares by several of its senior executives, including the CEO and CFO, under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning the interests of its leadership with those of its shareholders, potentially enhancing stakeholder confidence and reinforcing its market position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK, in partnership with iTeos Therapeutics, has decided to terminate the development of belrestotug, an anti-TIGIT monoclonal antibody, after interim analyses from phase 2 studies failed to meet efficacy criteria. This decision impacts GSK’s oncology strategy, which includes a shift towards other promising therapeutic areas, potentially affecting stakeholders involved in the belrestotug program.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 812,010 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a larger strategy to manage its capital structure, with the company now holding over 209 million shares in treasury. The buyback is expected to enhance shareholder value and reflects GSK’s confidence in its financial health and future prospects.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 650,432 of its own ordinary shares as part of its ongoing share buyback program. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited, aiming to enhance shareholder value by reducing the number of shares in circulation, which could potentially increase earnings per share and improve market perception.
GSK plc has announced the purchase of 699,344 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement initiated in February 2025, and it reflects the company’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and this transaction increases the total number of shares held in treasury to 206,209,407. The buyback program is a strategic effort to enhance shareholder value and optimize the company’s financial position.
GSK has announced the purchase of 709,955 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and aims to enhance shareholder value by holding these shares in treasury. The buyback program underscores GSK’s commitment to optimizing its capital structure and potentially improving its earnings per share, thereby strengthening its position in the healthcare industry.
GSK plc has announced its total voting rights and capital structure as of April 30, 2025, in accordance with the Financial Conduct Authority’s rules. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of 4.1 billion voting rights available to shareholders. This update is crucial for shareholders to calculate their interests and comply with regulatory requirements.
GSK announced positive results from the MATINEE phase III trial for Nucala (mepolizumab) in treating chronic obstructive pulmonary disease (COPD). The trial demonstrated significant reductions in COPD exacerbations, including a 21% reduction in moderate/severe exacerbations and a 35% reduction in exacerbations leading to emergency visits or hospitalizations. These findings highlight Nucala’s potential to improve patient outcomes and address a major healthcare challenge, as COPD-related hospitalizations are projected to become a leading cause of medical admissions.
GSK has announced the purchase of 685,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure and enhance shareholder value. Following this purchase, GSK holds over 204 million shares in treasury, with a total of over 4.1 billion shares in issue, excluding treasury shares. This move is likely to impact the company’s stock liquidity and could influence shareholder decisions regarding their interests in the company.
GSK reported a strong start to 2025 with significant growth in sales, profits, and earnings, driven by its Specialty Medicines segment. The company achieved a 4% increase in total Q1 sales to £7.5 billion, with notable contributions from oncology and respiratory medicines. GSK also highlighted its pipeline progress, expecting five major FDA product approvals in 2025, and emphasized its commitment to shareholder returns with a declared dividend and a share buyback program. The company remains confident in its 2025 guidance, projecting turnover growth of 3% to 5% and core operating profit growth of 6% to 8%, supported by strategic investments in R&D and operational efficiencies.
GSK has announced the purchase of 688,703 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which is in line with a non-discretionary agreement established earlier in the year, is aimed at consolidating the company’s shareholding structure, potentially enhancing shareholder value and reflecting confidence in its financial stability.
GSK has announced the purchase of 824,200 of its own ordinary shares as part of its ongoing share buyback program, facilitated by Citigroup Global Markets Limited. This move is part of a non-discretionary agreement aimed at optimizing the company’s capital structure, potentially enhancing shareholder value and reflecting confidence in the company’s financial health.
GSK has announced the purchase of 715,130 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially enhancing shareholder value.
GSK has announced the repurchase of 711,400 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which is part of a non-discretionary agreement, aims to manage the company’s capital structure and return value to shareholders, potentially enhancing shareholder confidence and stabilizing share prices.
GSK plc announced the purchase of 684,200 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and commitment to enhancing shareholder value. The shares will be held as treasury shares, and the total number of voting rights in the company remains unchanged at 4,115,579,330. This move is part of a broader strategy to optimize capital allocation and improve earnings per share, potentially impacting investor confidence and market perception positively.
GSK has announced the UK MHRA’s approval of Blenrep combinations for treating relapsed/refractory multiple myeloma, marking the first global authorization in this setting. The approval is based on superior efficacy results from the DREAMM-7 and DREAMM-8 phase III trials, which demonstrated significant improvements in progression-free and overall survival compared to standard treatments. This development positions Blenrep as a potentially transformative therapy in the treatment landscape, offering a differentiated mechanism of action and addressing the urgent need for more effective multiple myeloma treatments.
GSK plc has announced an increase in notional interest in its ordinary shares for several of its senior executives, including the CEO and CFO, following the reinvestment of dividends paid to shareholders. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
GSK announced that the US Advisory Committee on Immunization Practices has recommended the use of its RSV vaccine, Arexvy, for adults aged 50-59 who are at increased risk for severe RSV disease. This recommendation, which follows a successful phase III trial, could benefit over 13 million adults in the US and marks an expansion from previous recommendations for older age groups. The approval of this recommendation could significantly impact GSK’s operations by broadening the market for its RSV vaccine and offering protection to a larger segment of the population vulnerable to severe RSV outcomes.
GSK announced that its 5-in-1 meningococcal vaccine, Penmenvy, received a positive recommendation from the US Advisory Committee on Immunization Practices for use in individuals over 10 years old. This recommendation, if adopted, could simplify the vaccination process by reducing the number of injections required, potentially improving immunization rates among US adolescents and young adults. The vaccine, which combines components of GSK’s existing vaccines Bexsero and Menveo, is set to be available in the US by summer 2025. This development positions GSK to strengthen its market presence in the US, particularly in the MenB vaccine segment, where it already holds a significant share.
GSK has announced the purchase of 676,221 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through Citigroup Global Markets Limited, reflects the company’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, and the total number of voting rights remains unchanged, providing stakeholders with a stable basis for their investment calculations.
GSK PLC announced the purchase of 914,000 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares will be held as treasury shares, contributing to the company’s strategy to manage its capital structure effectively. This move is part of a non-discretionary agreement with the broker, reflecting GSK’s commitment to optimizing shareholder value and maintaining a robust financial position.
GSK plc announced the acquisition of ordinary shares by two key personnel, David Redfern, President of Corporate Development, and Victoria Whyte, Company Secretary. The shares were acquired following the reinvestment of dividends paid on April 10, 2025, and the transactions were conducted on the London Stock Exchange. This move reflects the company’s ongoing commitment to shareholder value and may positively impact investor confidence.
GSK has announced the purchase of 918,500 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategy to manage the company’s capital structure and return value to shareholders, with the purchased shares being held as treasury shares. The transaction reflects GSK’s commitment to enhancing shareholder value and maintaining a robust financial position.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by several of its independent non-executive directors, including Elizabeth McKee Anderson, Charles Bancroft, Dr. Hal Barron, Dr. Anne Beal, Dr. Harry Dietz, Dr. Jesse Goodman, and Dr. Jeannie Lee. These acquisitions were made following the reinvestment of dividends paid to shareholders on April 10, 2025. The transactions were conducted on the New York Stock Exchange at a price of $34.1210 per share. This move reflects the directors’ confidence in the company’s future performance and could potentially strengthen GSK’s market position by aligning the interests of its leadership with those of its shareholders.
GSK plc announced the purchase of 1,286,688 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at prices ranging from 1,268.00p to 1,299.50p, will be held in treasury. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited, initiated in February 2025, and highlights GSK’s strategy to manage its capital structure and return value to shareholders.
GSK announced the acquisition of ordinary shares by several of its top executives under the company’s Share Reward Plan. This move, involving key figures such as the CEO and CFO, signifies a strategic alignment of management interests with shareholder value, potentially strengthening stakeholder confidence and enhancing the company’s market positioning.
GSK has announced the purchase of 864,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares. This move is part of a non-discretionary agreement and contributes to the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GlaxoSmithKline (GSK) has announced a significant transaction involving the repurchase of 1,519,276 of its own ordinary shares, which will be held as treasury shares. This move is part of GSK’s ongoing buyback program, executed through Citigroup Global Markets Limited. The buyback is aimed at enhancing shareholder value and optimizing the company’s capital structure. Following this transaction, GSK holds a total of 194,312,216 ordinary shares in treasury, with the total number of voting rights standing at 4,120,914,866.
GSK has announced the purchase of 1,035,000 of its own ordinary shares, as part of its ongoing buyback program, through Citigroup Global Markets Limited. The shares, bought at an average price of 1,345.28 pence, will be held as treasury shares. This transaction, part of a non-discretionary agreement, reflects GSK’s strategy to optimize its capital structure and potentially enhance shareholder value. The company now holds 192,792,940 shares in treasury, with 4,122,434,142 shares in issue, impacting the total voting rights available to shareholders.
GSK has announced the purchase of 1,454,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement initiated in February 2025, and the shares will be held as treasury shares. The buyback program is a strategic effort to manage the company’s capital structure and return value to shareholders, reflecting GSK’s confidence in its financial health and future prospects.
GSK has announced the repurchase of 808,000 of its ordinary shares as part of its ongoing buyback program. This transaction, facilitated by Citigroup Global Markets Limited, reflects GSK’s strategy to enhance shareholder value and optimize its capital structure. The shares, purchased at prices ranging from 1,413.00p to 1,468.50p, will be held as treasury shares, contributing to a total of 190,303,940 shares in treasury. This move underscores GSK’s commitment to returning value to its shareholders and maintaining a strong financial position.
GSK has announced the purchase of 739,200 of its own ordinary shares as part of its ongoing share buyback program. This move, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to optimize its capital structure and enhance shareholder value. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially impacting its market positioning by reducing the number of shares available in the market.
GSK has announced the purchase of 819,550 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially impacting shareholder voting rights.
GSK has announced a recent transaction involving the repurchase of 630,000 of its ordinary shares, as part of its ongoing buyback program. This move, executed through Citigroup Global Markets Limited, aims to consolidate the company’s share capital and potentially enhance shareholder value by holding these shares in treasury. The buyback reflects GSK’s strategic financial management and may influence shareholder interest calculations under regulatory guidelines.
GSK plc has announced its total voting rights and capital as of March 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company’s issued share capital consists of over 4.3 billion shares, with 187 million held in treasury, resulting in a total of approximately 4.1 billion voting rights. This information is crucial for shareholders to determine their notification requirements under regulatory guidelines.
GSK announced the purchase of 836,600 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This action is part of a non-discretionary agreement initiated in February 2025, and the shares will be held in treasury, impacting the company’s share structure and potentially influencing shareholder value.
GSK has announced the purchase of 834,200 of its own ordinary shares, which will be held as treasury shares. This transaction is part of the company’s ongoing buyback program, executed through Citigroup Global Markets Limited. The buyback is aimed at optimizing the company’s capital structure and enhancing shareholder value. Following this purchase, GSK holds a total of 186,470,590 ordinary shares in treasury, with 4,128,751,142 shares in issue. This move may influence shareholder voting rights and is a strategic step in GSK’s financial management.
GSK plc has announced the release of American Depositary Shares (ADSs) for several of its non-executive directors following the termination of the GSK Non-Executive Director Share Allocation Arrangements. The directors, including Charles Bancroft, Dr Anne Beal, Dr Hal Dietz, and Dr Jesse Goodman, have received their respective ADSs, with a portion withheld for tax purposes. These shares will be held by the directors until their retirement from the board, reflecting a strategic move in managing executive compensation and aligning with shareholder interests.
GSK plc has announced the purchase of 847,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and may influence shareholder value by reducing the number of shares in circulation, potentially increasing earnings per share.
GlaxoSmithKline (GSK) has announced the purchase of 847,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares, contributing to a total of 184,789,390 shares in treasury. This move is part of a non-discretionary agreement initiated on 24 February 2025, and since then, GSK has repurchased a total of 15,719,087 shares. The buyback program is a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
GSK has announced the purchase of 835,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which involves holding the shares in treasury, is part of a non-discretionary agreement initiated in February 2025, and it reflects GSK’s strategy to manage its capital structure and enhance shareholder value.
GSK plc announced the purchase of 587,100 of its own ordinary shares as part of its ongoing share buyback program. The shares were acquired at prices ranging from 1,482.00p to 1,516.00p, with a volume-weighted average price of 1,490.87p. This transaction, executed through Citigroup Global Markets Limited, adds to the 14,037,087 shares already repurchased since February 2025, reflecting GSK’s strategy to enhance shareholder value and optimize its capital structure.
GSK announced that the US FDA has approved Blujepa (gepotidacin), a first-in-class oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients aged 12 and older. This approval marks a significant milestone as Blujepa is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing the growing issue of drug-resistant bacteria. The approval is based on positive results from phase III EAGLE-2 and EAGLE-3 trials, which demonstrated Blujepa’s efficacy and safety compared to the standard treatment, nitrofurantoin. The commercial launch in the US is planned for the second half of 2025, and the development has been partially funded by US federal agencies.
GSK announced that the European Medicines Agency has accepted its application to expand the use of Nucala (mepolizumab) for treating COPD with an eosinophilic phenotype. The application is backed by the successful phase III MATINEE trial, which demonstrated a significant reduction in moderate/severe exacerbations in COPD patients. If approved, Nucala could become the first monthly biologic treatment for COPD, addressing a major need for targeted therapies in a disease affecting over 40 million people in Europe.
GSK has announced the purchase of 570,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement and reflects GSK’s strategic approach to managing its capital structure, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
GSK plc announced transactions involving the purchase of shares by several of its board members, including Sir Jonathan Symonds, Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, and Dr Jesse Goodman. These transactions, conducted on March 20, 2025, involved the acquisition of both Ordinary Shares on the London Stock Exchange and American Depositary Shares on the New York Stock Exchange. The purchases reflect confidence in the company’s future prospects and may influence investor perception positively.
GSK plc has announced the purchase of 565,320 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic move to manage its capital structure and potentially enhance shareholder value by holding these shares in treasury.
GSK has announced the purchase of 556,200 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on March 19, 2025, is part of a non-discretionary agreement and highlights GSK’s strategic efforts to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and the total number of voting rights remains unchanged at 4,133,820,322, providing stakeholders with a clear understanding of their shareholding status.
GSK has announced the purchase of 552,000 of its own ordinary shares as part of its ongoing share buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a broader strategy to manage capital structure and return value to shareholders, reflecting GSK’s commitment to maintaining a robust financial position and enhancing shareholder value.
GSK has announced the purchase of 745,425 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on 17 March 2025, reflects GSK’s strategic initiative to manage its capital structure and enhance shareholder value by holding these shares in treasury, thereby potentially impacting the company’s stock market performance and investor relations.
GSK announced the purchase of 690,000 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which involved shares priced between 1,495.50p and 1,513.50p, aims to consolidate the company’s capital structure by holding the acquired shares as treasury shares, thereby potentially enhancing shareholder value.
GSK plc announced the acquisition of ordinary shares by several of its senior executives, including the CEO and CFO, under the company’s Share Reward Plan. Each executive acquired 16 ordinary shares at a price of £15.4540 per share, with transactions conducted on the London Stock Exchange. This move reflects the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence in GSK’s strategic direction.
GSK announced the purchase of 755,000 of its own shares as part of an ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on 13 March 2025, is part of a strategy to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and the company now holds a total of 178,841,345 shares in treasury. This move is expected to impact the company’s financial metrics and shareholder value positively.
GSK plc announced the purchase of 755,000 of its own ordinary shares as part of its ongoing buyback program, executed through its broker, Citigroup Global Markets Limited. This transaction is part of a non-discretionary agreement and contributes to the company’s strategy of managing its capital structure efficiently, potentially enhancing shareholder value.
GSK plc announced the purchase of 724,000 of its own ordinary shares, as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares, bought at a volume-weighted average price of 1,525.77 pence, will be held as treasury shares, contributing to a total of 177,331,345 shares in treasury. This move is part of a strategic effort to manage the company’s capital structure and enhance shareholder value.
GSK has announced the purchase of 508,000 of its own ordinary shares, which will be held as treasury shares, as part of its ongoing buyback program. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited, aiming to manage the company’s capital structure and return value to shareholders.
GlaxoSmithKline (GSK) announced the purchase of 500,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which involved shares priced between 1,497.00p and 1,535.00p, contributes to GSK’s strategy to manage its capital structure and return value to shareholders, with a total of 7,029,042 shares purchased since the program’s initiation.
GSK announced the purchase of 782,440 of its own ordinary shares as part of its ongoing buyback program, with the shares to be held as treasury shares. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The buyback program, initiated on February 24, 2025, has seen a total of 5,821,342 shares repurchased, indicating a significant commitment to this financial strategy.
GSK plc has announced the purchase of 547,800 of its own ordinary shares, as part of its ongoing buyback program, through its broker Citigroup Global Markets Limited. This transaction, executed on March 4, 2025, is part of a non-discretionary agreement and reflects the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GSK has announced the repurchase of 547,800 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategic effort to manage its capital structure and enhance shareholder value, with the shares being held in treasury. The company now holds a total of 174,109,205 shares in treasury, with 4,141,068,225 shares in issue, excluding treasury shares, impacting the total number of voting rights available to shareholders.
GSK announced the purchase of 537,500 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares, bought at prices ranging from 1,469.00p to 1,495.00p, will be held as treasury shares. This move is part of a strategic effort to manage capital and enhance shareholder value, reflecting GSK’s commitment to maintaining a robust financial position and potentially impacting its market valuation positively.
GSK has filed its 2024 Annual Report on Form 20-F with the SEC, which includes audited financial statements for the year ending December 31, 2024. The report is accessible online, and shareholders can request a hard copy. This filing is a routine disclosure that provides transparency and accountability to shareholders and stakeholders, reinforcing GSK’s commitment to regulatory compliance and financial transparency.
GSK plc has announced its total voting rights and capital structure as of February 28, 2025. The company reported an issued share capital of 4,315,177,430 shares, with 173,023,905 shares held in treasury, resulting in a total of 4,142,153,525 voting rights. This information is crucial for shareholders to determine their interests under the Financial Conduct Authority’s rules, impacting their decision-making and compliance obligations.
GSK announced that the US FDA has accepted the Biologics License Application for depemokimab, a monoclonal antibody targeting IL-5, for review as a treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab will be the first ultra-long-acting biologic with a six-month dosing regimen, potentially reducing the burden on patients and healthcare systems. The SWIFT and ANCHOR trials demonstrated depemokimab’s efficacy in reducing asthma exacerbations and nasal polyp size, highlighting its potential to improve patient care and adherence to treatment.
GSK plc has announced the repurchase of 542,550 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, completed on February 28, 2025, is part of a non-discretionary agreement and contributes to the company’s strategy of managing its capital structure. The shares will be held in treasury, impacting the total number of voting rights and potentially affecting shareholder interests in line with the Financial Conduct Authority’s rules.
GSK announced positive results from its ANCHOR-1 and ANCHOR-2 phase III trials for depemokimab, a monoclonal antibody targeting IL-5, in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated significant improvements in nasal polyp size and obstruction with a twice-yearly dosing regimen. These findings, presented at the AAAAI/WAO Joint Congress and published in The Lancet, highlight depemokimab’s potential as an alternative to current treatments, which often require repeat surgeries and long-term corticosteroid use. The results could impact regulatory filings and support the drug’s use in other IL-5 mediated diseases.
GlaxoSmithKline (GSK) has announced a significant transaction involving the repurchase of its own shares. The company, through its broker Citigroup Global Markets Limited, has acquired 800,000 ordinary shares as part of its existing buyback program. This move is part of a broader strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held in treasury, and the total number of voting rights in the company remains unchanged at 4,142,685,716. This transaction reflects GSK’s ongoing commitment to optimizing its financial operations and maintaining a robust market presence.